Manufacturer of eflornithine

Eflornithine was originally developed for cancer treatment at the Merrell Dow Institute in the late 1970s, but was found to be ineffective in treating malignant tumors. However, it has been found to be very effective in slowing hair growth, as well as in the treatment of African trypanosomiasis, especially the West African type (Trypanosoma brucei subspecies gambiae). 20Century80In the 1980s, Gillette was patented for discovering that topical eflornithine hydrochloride cream could inhibit hair growth. In the 1920s and 1990s, Gillette conducted a dose-ranging study of eflornithine in hirsute women, demonstrating that the drug slowed the growth of facial hair. Gillette subsequently applied for a patent on the eflornithine cream formula. In July 2000, the U.S. Food and Drug Administration (FDA) granted a new drug application for Vaniqa. The following year, the European Commission issued marketing authorization.